文献速递痛风与晶体性关节病

代谢组学特征预测秋水仙碱预防下痛风发作临床结局

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis.
PubMed 文献 · Arthritis Rheumatol · 2026-03-13

本研究为多中心前瞻性队列(n=409),在痛风患者启动达标降尿酸治疗(ULT)前检测血清代谢组,以评估其对秋水仙碱预防反应性的预测价值。结果显示,一种四代谢物风险评分与痛风发作活动显著相关(校正HR 3.21,95%CI 2.24-4.59),机器学习模型预测发作风险的AUC在发现队列和验证队列分别为0.771(95%CI 0.713-0.828)和0.724(95%CI 0.611-0.837)。

要点

  • 基线血清代谢组可预测秋水仙碱预防下痛风发作风险。
  • 四代谢物风险评分与发作活动独立相关(校正HR 3.21)。
  • 机器学习模型联合代谢物与临床因素预测发作AUC达0.771。

核心结论

  • 代谢组学定义的炎症状态与接受秋水仙碱预防的ULT启动者的痛风发作结局相关。
  • 在ULT前识别的新型代谢组预测特征可能有助于优化痛风患者启动达标ULT后前六个月的秋水仙碱预防剂量与疗程决策。

研究设计与样本

  • 多中心前瞻性队列研究,纳入409例启动达标降尿酸治疗(ULT)联合秋水仙碱预防的痛风患者。
  • 入组时检测非靶向代谢组学,定义秋水仙碱反应者为首次秋水仙碱剂量后六个月内无发作,无反应者为一次或以上发作。
  • 采用Cox回归和机器学习模型定义与秋水仙碱预防期间发作活动相关的代谢组特征。

主要发现

  • 队列中36.9%的参与者经历至少一次发作。
  • 复发性发作组中多种炎症相关代谢物丰度存在差异,并与复发性发作风险相关。
  • 四代谢物风险评分与痛风发作活动显著相关(校正HR 3.21,95%CI 2.24-4.59),独立于校正的临床因素。
  • 机器学习模型结合多变量方法筛选的顶级代谢物及传统临床因素,预测发作风险的AUC在发现队列为0.771(95%CI 0.713-0.828),在验证队列为0.724(95%CI 0.611-0.837)。

临床怎么用

  • 在启动达标ULT前检测血清代谢组学可能有助于识别秋水仙碱预防下高发作风险的痛风患者。
  • 代谢组学预测特征或可辅助优化秋水仙碱预防的剂量与疗程决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigated that serum metabolomics, before urate-lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat-to-target ULT. METHODS: We studied a multicenter prospective cohort (n = 409) initiating treat-to-target ULT plus colchicine prophylaxis. Untargeted metabolomics were measured at enrollment. We defined putative colchicine response or colchicine nonresponse as no flare or one or more flares, respectively, during six months after first colchicine dose. Cox regression and machine learning models defined the metabolomic signatures associated with reported flare activity on colchicine prophylaxis in the cohort. RESULTS: In our cohort, 36.9% participants experienced at least one flare. Many inflammation-related metabolites were differentially abundant in the recurrent flare group and correlated with recurrent flare risk. A significant association was found between a four-metabolite risk score and gout flare activity (adjusted hazard ratio 3.21, 95% confidence interval [CI] 2.24-4.59), independent of the adjusted clinical factors. The machine learning model, which incorporated the top-ranked metabolites selected by multivariable methods with unbiased variable selection along with traditional clinical factors, reached an area under the receiver operating characteristic of 0.771 (95% CI 0.713-0.828) and 0.724 (95% CI 0.611-0.837) for predicting flare risk in the discovery and validation cohort, respectively. CONCLUSION: Metabolomic profile-defined inflammation status was associated with gout flare outcomes in ULT initiators receiving colchicine prophylaxis. Identification of these novel metabolomic predictive signatures before ULT could potentially help optimize clinical decision-making for flare prophylaxis colchicine dosing and duration in the first six months after initiation of treat-to-target ULT in gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Sun W, Xu L, Chen H, et al. A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis. Arthritis Rheumatol. 2026. PMID: 41711532. doi:10.1002/art.70094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。